Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : NEOTHERAPEUTICS (NEOT) (NEOTW) -- Ignore unavailable to you. Want to Upgrade?

To: TFF who wrote (339)	5/20/1998 10:27:00 PM
From: MoneyMade	Respond to of 705

SYMBOL ADVR READ ALL: The next AZT... 98th General Meeting of the American Society for Microbiology May 17-21, 1998, Atlanta, Georgia Controlled Trial of a New Non-Toxic Drug, Reticulose, in the Treatment of Patients with HIV/AIDS Paul Levett University of West Indies School of Clinical Medicine and Research Queen Elizabeth Hospital Barbados 246-427-5586 A-263, Session 252 A trial of this new treatment for HIV/AIDS suggests that it can stimulate the immune system to produce increased CD4 cells without an accompanying rise in HIV viral load.Patients who received Reticulose also gained weight and their clinical condition improved compared to controls.The study was conducted by a team from the University of the West Indies School of Clinical Medicine & Research at the Queen Elizabeth Hospital in Barbados. The team included Dr. Paul N. Levett (clinical microbiologist), Dr. Timothy C. Roach (internal medicine specialist) Dr. Henry S. Fraser (internal medicine specialist), and Ms. Hedy Broome (biostatistician) in collaboration with Dr. Shalom Z. Hirschman, New York-based infectious diseases specialist. Dr. Hirschman is President and CEO of Advanced Viral Research Corp. Yonkers, NY, which manufactures Reticulose and which supported the study.The first presentation of data from this study is to be made at the 98th General Meeting of the American Society for Microbiology, in Atlanta, Georgia, on Thursday, May 21, 1998. A total of 43 patients with HIV-1 infection, who had never received anti-retroviral therapy, were randomized to receive either Reticulose (21 patients) or placebo (22 patients), at a dosage of two 1ml subcutaneous (SC) injections per day for two weeks, followed by 1ml SC per day every other week for a total of 60 days (total 30 days treatment). There were no toxic effects observed in, or reported by, patients receiving Reticulose. In patients with HIV-1 infection, treatment with Reticulose produced an early rise in CD4 counts, with no accompanying rise in plasma HIV RNA levels during this limited period of observation. There were improved clinical outcomes, including weight gain, fewer opportunistic infections and lower mortality in patients who received Reticulose. These findings, and the low cost of Reticulose, could have major implications for alternative treatments for the global patient population with HIV/AIDS. Reticulose is a peptide nucleic acid which acts as an immunomodulator, stimulating the production of cytokines. Other viral infections for which trials of Reticulose are presently underway include hepatitis B and human papillomavirus (HPV) asmusa.org Stock SYMBOL (ADVR)

To: TFF who wrote (339)	5/20/1998 10:57:00 PM
From: topwright	Read Replies (1) \| Respond to of 705

There is much to be celebrating in a stock that just doubled, but I'm afraid a lot of you are looking through rose colored glasses at an other wise highly speculative situation with little substance to sustain a higher price. It is my suggestion that you explore some of the exceptional circumstances that surround today's run-up. Today's volatility was the direct result of trader induced exuberance in an otherwise boring day caused by the galaxy 4 satellite going down. Traders were looking for anything to punch up. Ask yourselves why it took since the 11th for the news to get discoverd? Take a good look at what you got here, a company that is losing .46 EPS per qtr, burning close to 6 mill per year, just recently did a $15 milllion equity financing deal, and just completed Phase I clinical trials which basically determine that the subjects don't die of the drug or have severe side effects. In the next phase, which won't truly get underway until mid summer will accelerate even further the burn rate of money. No preliminary results are expected before late year. There is a good chance that if the street is back to normal tomorrow morning you will see just the opposite effect from what you are proposing. Remember this news was out since 5/11, and even had prior notification to that date revealing the same information that made it run today. Don't take this wrong, all I'm trying to do is alert you to the possiblility that it may get the rug ripped early on, especially with CNBC planning to do a ditty on it whereby it may not be so rosy. They know they were behind the runup today so there is good chance tomorrows highlight may emphasize the cavaets. Good luck, hope you all make a kazillion. rb